Have a personal or library account? Click to login
KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician Cover

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician

Open Access
|Sep 2019

Figures & Tables

Figure 1

Flow chart of the search for the eligible studies.
Flow chart of the search for the eligible studies.

Figure 2

Summary features of biomarkers in stage IV colorectal cancer
EGFR = epithelial growth factor receptor; FOLFOXIRI = regimen of chemotherapy consisting of 5-fluorouracil, folinic acid, oxaliplatin and irinotecan; MMR = mismatch repair; MSI = microsatellite instability; OS = overall survival; WT = wild type
Summary features of biomarkers in stage IV colorectal cancer EGFR = epithelial growth factor receptor; FOLFOXIRI = regimen of chemotherapy consisting of 5-fluorouracil, folinic acid, oxaliplatin and irinotecan; MMR = mismatch repair; MSI = microsatellite instability; OS = overall survival; WT = wild type
DOI: https://doi.org/10.2478/raon-2019-0033 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 265 - 274
Submitted on: Feb 16, 2019
|
Accepted on: Jun 24, 2019
|
Published on: Sep 24, 2019
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2019 Vlad-Adrian Afrăsânie, Mihai Vasile Marinca, Teodora Alexa-Stratulat, Bogdan Gafton, Marius Păduraru, Anca Maria Adavidoaiei, Lucian Miron, Cristina Rusu, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.